Oncopeptides AB issues 977,906 shares additionally in connection with offer to acquire shares and listing on Nasdaq Stockholm (the “Offering”)

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

On 26 March 2017, the board of directors of Oncopeptides, pursuant to the request by the Joint Global Coordinators (defined below), resolved to issue 977,906 shares to ABG Sundal Collier AB. Oncopeptides will thereby be provided with additional funds of approximately SEK 45 million, which means that the Company will have been provided with a total of approximately SEK 695 million through the Offering, before deduction of issue expenses.

For more information please visit: www.oncopeptides.se 

This information is such that Oncopeptides is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on 27 March 2017 at 08.00 a.m. (CET).